Product Description
Mechanisms of Action: Proteasome Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Teva
Company Location: PETACH TIKVA L3 49131
Company CEO: Kåre Schultz
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Multiple Myeloma
Phase 1: Lymphoma, Non-Hodgkin
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00572637 |
E-CEP\I\01 | P1 |
Completed |
Lymphoma, Non-Hodgkin |
2010-03-01 |
2019-03-22 |
Treatments |
|
NCT01348919 |
C18770/2049 | P2 |
Completed |
Multiple Myeloma |
2013-03-14 |
2023-05-22 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
2009-013778-41 |
2009-013778-41 | P2 |
Completed |
Multiple Myeloma |
2012-11-15 |
2022-03-13 |
Treatments |
|
NCT01023880 |
C18770/2043 | P2 |
Terminated |
Multiple Myeloma |
2012-11-01 |
2019-03-19 |
Treatments |